Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AVNS NASDAQ:AXGN NASDAQ:BBNX NASDAQ:PDEX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVNSAvanos Medical$11.00-1.6%$12.11$10.86▼$25.36$516.54M1.12434,917 shs670,789 shsAXGNAxoGen$12.67-3.2%$11.22$7.34▼$21.00$596.17M11.39 million shs1.56 million shsBBNXBeta Bionics$16.40-2.3%$15.71$8.89▼$24.50$729.86MN/A527,705 shs514,719 shsPDEXPro-Dex$47.35-5.4%$44.75$17.81▼$70.26$163.21M0.1950,117 shs43,246 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVNSAvanos Medical-1.48%-8.44%-10.96%-10.46%-53.92%AXGNAxoGen-3.21%-5.24%+14.56%-26.04%+44.31%BBNXBeta Bionics-2.32%+10.51%+15.98%+38.63%+1,639,999,900.00%PDEXPro-Dex-5.39%-4.21%+5.11%+3.25%+134.17%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVNSAvanos Medical2.3294 of 5 stars0.03.00.00.02.61.72.5AXGNAxoGen2.3714 of 5 stars3.51.00.00.02.52.50.6BBNXBeta Bionics2.3305 of 5 stars4.40.00.00.01.90.80.0PDEXPro-Dex2.3423 of 5 stars2.51.00.00.03.71.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVNSAvanos Medical 0.00N/AN/AN/AAXGNAxoGen 3.00Buy$24.5093.37% UpsideBBNXBeta Bionics 2.75Moderate Buy$22.5637.53% UpsidePDEXPro-Dex 3.00Buy$56.0018.27% UpsideCurrent Analyst Ratings BreakdownLatest PDEX, BBNX, AXGN, and AVNS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/30/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $21.007/30/2025BBNXBeta BionicsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetNeutral ➝ Neutral$15.00 ➝ $17.006/16/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$26.006/12/2025BBNXBeta BionicsLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy ➝ Buy$30.005/30/2025BBNXBeta BionicsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$16.005/30/2025BBNXBeta BionicsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$20.005/27/2025PDEXPro-DexAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $56.005/13/2025AXGNAxoGenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $24.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVNSAvanos Medical$687.80M0.74$11.70 per share0.94$18.03 per share0.61AXGNAxoGen$187.34M3.08N/AN/A$2.36 per share5.37BBNXBeta Bionics$65.12M10.95N/AN/A$6.94 per share2.36PDEXPro-Dex$53.84M2.87$0.91 per share52.27$9.03 per share5.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVNSAvanos Medical-$392.10M-$8.37N/A6.36N/A-55.80%6.26%4.63%8/5/2025 (Estimated)AXGNAxoGen-$9.96M-$0.15N/AN/AN/A-3.68%-7.09%-3.67%8/5/2025 (Estimated)BBNXBeta Bionics-$54.76MN/A0.00∞N/AN/AN/AN/AN/APDEXPro-Dex$2.13M$2.8016.9122.99N/A14.61%29.08%16.19%9/4/2025 (Estimated)Latest PDEX, BBNX, AXGN, and AVNS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025AVNSAvanos Medical$0.18N/AN/AN/A$165.50 millionN/A8/5/2025Q2 2025AXGNAxoGen$0.06N/AN/AN/A$52.61 millionN/A7/29/2025Q2 2025BBNXBeta Bionics-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 million5/6/2025Q1 2025AVNSAvanos Medical$0.19$0.26+$0.07$0.14$161.75 million$167.50 million5/6/2025Q1 2025BBNXBeta Bionics-$0.51-$0.52-$0.01-$0.93N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVNSAvanos MedicalN/AN/AN/AN/AN/AAXGNAxoGenN/AN/AN/AN/AN/ABBNXBeta BionicsN/AN/AN/AN/AN/APDEXPro-DexN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVNSAvanos Medical0.122.571.56AXGNAxoGen0.634.282.65BBNXBeta BionicsN/A14.6814.93PDEXPro-Dex0.282.731.45Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVNSAvanos Medical95.17%AXGNAxoGen80.29%BBNXBeta BionicsN/APDEXPro-Dex15.28%Insider OwnershipCompanyInsider OwnershipAVNSAvanos Medical2.64%AXGNAxoGen2.78%BBNXBeta BionicsN/APDEXPro-Dex47.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVNSAvanos Medical2,22746.24 million45.02 millionOptionableAXGNAxoGen45045.54 million44.28 millionOptionableBBNXBeta Bionics29443.47 millionN/AN/APDEXPro-Dex1403.26 million1.71 millionNot OptionablePDEX, BBNX, AXGN, and AVNS HeadlinesRecent News About These CompaniesPro-Dex (NASDAQ:PDEX) versus McKesson (NYSE:MCK) Head-To-Head SurveyAugust 1 at 2:55 AM | americanbankingnews.comStrength Seen in ProDex (PDEX): Can Its 8.2% Jump Turn into More Strength?July 29, 2025 | zacks.comNavellier & Associates Inc. Purchases New Shares in Pro-Dex, Inc. (NASDAQ:PDEX)July 27, 2025 | marketbeat.comPro-Dex (NASDAQ:PDEX) vs. McKesson (NYSE:MCK) Financial AnalysisJuly 26, 2025 | americanbankingnews.comPro-Dex (NASDAQ:PDEX) Shares Pass Above 200 Day Moving Average - Time to Sell?July 26, 2025 | marketbeat.comPro-Dex, Inc. (PDEX) - Yahoo FinanceJuly 16, 2025 | finance.yahoo.comNew Strong Buy Stocks for July 1stJuly 1, 2025 | zacks.comBest Value Stocks to Buy for July 1stJuly 1, 2025 | zacks.comPro-Dex, Inc. (PDEX) Stock Price, Quote, News & Analysis - Seeking AlphaJune 27, 2025 | seekingalpha.comInvestors Shouldn't Overlook The Favourable Returns On Capital At Pro-Dex (NASDAQ:PDEX)June 23, 2025 | finance.yahoo.comHere is Why Growth Investors Should Buy ProDex (PDEX) NowJune 17, 2025 | zacks.comProDex (PDEX) Upgraded to Buy: Here's WhyJune 17, 2025 | zacks.comAre Pro-Dex, Inc.'s (NASDAQ:PDEX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?May 20, 2025 | finance.yahoo.comPro-Dex: Crash After Strong Earnings Leads To A Buying OpportunityMay 5, 2025 | seekingalpha.comHere's Why Pro-Dex (NASDAQ:PDEX) Has Caught The Eye Of InvestorsMay 4, 2025 | uk.finance.yahoo.comPro-Dex, Inc. (PDEX) Q3 Earnings Surpass EstimatesMay 1, 2025 | zacks.comPro-Dex, Inc. Announces Fiscal 2025 Third Quarter and Nine-Month ResultsMay 1, 2025 | accessnewswire.comAProDex (PDEX) Moves 5.1% Higher: Will This Strength Last?April 25, 2025 | zacks.comTake the Zacks Approach to Beat the Markets: Pro-Dex, Brookdale Senior Living, Coca-Cola in FocusApril 21, 2025 | zacks.comProDex (PDEX) Surges 7.4%: Is This an Indication of Further Gains?April 3, 2025 | zacks.comPro-Dex, Inc. (NASDAQ:PDEX) Director Raymond E. Cabillot Sells 842 SharesApril 2, 2025 | insidertrades.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePDEX, BBNX, AXGN, and AVNS Company DescriptionsAvanos Medical NYSE:AVNS$11.00 -0.18 (-1.57%) Closing price 08/1/2025 03:59 PM EasternExtended Trading$11.26 +0.27 (+2.41%) As of 08/1/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avanos Medical, Inc., a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions. The company also provides a portfolio of non-opioid pain solutions, including surgical pain and recovery products, such as ON-Q and ambIT surgical pain pumps, Game Ready cold, and compression therapy systems. In addition, it offers interventional pain solutions, which offers minimally invasive pain-relieving therapies, such as Coolief pain relief therapy; OrthogenRx's knee osteoarthritis hyaluronic acid pain relief injection products; and Trident radiofrequency ablation products to treat chronic pain conditions. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.AxoGen NASDAQ:AXGN$12.67 -0.42 (-3.21%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$12.71 +0.04 (+0.28%) As of 08/1/2025 06:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Beta Bionics NASDAQ:BBNX$16.40 -0.39 (-2.32%) As of 08/1/2025 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Pro-Dex NASDAQ:PDEX$47.35 -2.70 (-5.39%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$47.25 -0.10 (-0.21%) As of 08/1/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pro-Dex, Inc. designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets. It also provides engineering, quality, and regulatory consulting services; and manufactures and sells rotary air motors to various industries. The company's products are used in hospitals, medical engineering labs, scientific research facilities, and high-tech manufacturing operations. Pro-Dex, Inc. was founded in 1978 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
